MSD's Gardasil sales slide further due to China constraints [Yahoo! Finance]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Yahoo! Finance
During MSD's Q1 2025 earnings call on 24 April, chief financial officer Caroline Litchfield said MSD does not expect to resume Gardasil shipments to China before mid-year, following a suspension announced back in February. Q1 2025 Gardasil sales totalled $1.3bn, down from $2.2bn in Q1 2024. Excluding the impact of foreign exchange, the decline was 40%. Despite the setback in China, the company said the revenue drop was partially offset by stronger demand in the US and Japan. Outside of China, Gardasil sales grew 14%, or 16% on a constant currency basis. Litchfield acknowledged that China would continue to be a hang heavy on the company's vaccine performance this year: “As we look to Gardasil globally this year, we expect China to be a headwind…expect, given the current dynamics in China, that it is not so likely that we will ship further product in China.” The suspension in shipments came amidst a challenging environment in China, where a combination of regulatory scrutiny, gro
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Olema: 'Strong Buy' Maintained On OPERA-02 Trial Initiation & Additional Shots On Goal [Seeking Alpha]Seeking Alpha
- 2 Top Stocks to Buy and Hold for the Long Term [Yahoo! Finance]Yahoo! Finance
- Nine Drugmakers Strike Deals With Trump, More Coming Next Year [Yahoo! Finance]Yahoo! Finance
- Novartis and US government reach agreement on lowering drug prices in the US [Yahoo! Finance]Yahoo! Finance
- Novartis' myasthenia gravis asset iptacopan granted FDA Orphan Drug status [Seeking Alpha]Seeking Alpha
NVS
Earnings
- 10/28/25 - Miss
NVS
Sec Filings
- 11/25/25 - Form 6-K
- 11/20/25 - Form 6-K
- 11/5/25 - Form 6-K
- NVS's page on the SEC website